Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Revenue of Minerva Surgical, Inc. (UTRS)
Revenue in 2022 (TTM): $50.29 M
According to Minerva Surgical, Inc.'s latest financial reports the company's current revenue (TTM) is $50.29 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Minerva Surgical, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $50.29 M | $27.24 M | $-30,879,000 | $-34,101,000 | $-34,112,000 |
| 2021 | $52.1 M | $30.52 M | $-18,855,000 | $-21,455,000 | $-21,464,000 |
| 2020 | $37.77 M | $19.12 M | $-8,162,000 | $-18,395,000 | $-18,263,000 |
| 2019 | $26.01 M | $11.81 M | $-17,656,000 | $-52,046,000 | $-69,796,000 |